Investigating the Different Dimensions of DPP-4 Inhibitors - European Medical Journal

This site is intended for healthcare professionals

Investigating the Different Dimensions of DPP-4 Inhibitors

Diabetes
Download PDF
Chairperson:
Heinz Drexel 1
Speakers:
Jørgen Rungby , 2 Jochen Seufert , 3 Kausik Ray 4
Acknowledgements:

Writing assistance was provided by Dr Tabasum Mughal of apothecom scopemedical Ltd.

Keywords:
EASD, European Association for the Study of Diabetes
Citation:
EMJ Dermatol. ;3[1]:35-41. DOI/10.33590/emjdiabet/10310228. https://doi.org/10.33590/emjdiabet/10310228.
Support:

Medical writing assistance was funded by Takeda. The views and opinions expressed are those of the authors as expressed during the symposium and not necessarily of Takeda.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

This Takeda-sponsored European Association for the Study of Diabetes (EASD) symposium addressed the pharmacology, clinical use, and future therapeutic application of dipeptidyl-peptidase-4 (DPP-4) inhibitors. The scientific programme covered the clinical efficacy of DPP-4 inhibitors, their durability in clinical practice, and their use in combination therapy with other antidiabetic drugs. The important issue of the effect of this class of drugs on cardiovascular (CV) outcomes was also explored. The symposium was chaired by Prof Heinz Drexel and included insightful talks from an expert faculty comprising of Profs Jørgen Rungby, Jochen Seufert, and Kausik Ray.

Please view the full content in the pdf above.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.